Verastem, Inc. (VSTM) News

Verastem, Inc. (VSTM): $1.26

0.02 (+1.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VSTM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 396

in industry

Filter VSTM News Items

VSTM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VSTM News Highlights

  • VSTM's 30 day story count now stands at 2.
  • Over the past 19 days, the trend for VSTM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • SA and VALE are the most mentioned tickers in articles about VSTM.

Latest VSTM News From Around the Web

Below are the latest news stories about Verastem Inc that investors may wish to consider to help them evaluate VSTM as an investment opportunity.

Verastem (NASDAQ:VSTM) investors are sitting on a loss of 62% if they invested three years ago

If you love investing in stocks you're bound to buy some losers. But the long term shareholders of Verastem, Inc...

Yahoo | February 22, 2022

Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ...

Investment company Kalos Management, Inc. (Current Portfolio) buys Vale SA, sells Consensus Cloud Solutions Inc, Intuitive Surgical Inc, Amarin Corp PLC, Catalyst Biosciences Inc, Paratek Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Kalos Management, Inc..

Yahoo | February 3, 2022

Verastem Oncology outlines key milestones for 2022

Verastem Oncology (VSTM) announces key strategic priorities and upcoming catalysts to support its lead compound VS-6766 in 2022.The company expects to reports results from RAMP 201

Seeking Alpha | January 11, 2022

Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers

BOSTON, January 11, 2022--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and upcoming catalysts to support its lead compound VS-6766 in 2022. VS-6766 is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF, potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition. VS-6766 is currently in late-stage d

Yahoo | January 11, 2022

Verastem Oncology grants under nasdaq listing rule 5635(c)(4)

Verastem Oncology (VSTM) grants inducement options to purchase 1,625 shares of its common stock and the grant of 813 restricted stock units (RSUs) to two new employees.The options have

Seeking Alpha | January 7, 2022

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, January 07, 2022--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase 1,625 shares of its common stock and the grant of 813 restricted stock units (RSUs) to two new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees’ acceptance of employment with Verastem Oncology in accordance with Nasdaq

Yahoo | January 7, 2022

Verastem Oncology to Participate in Upcoming Investor Conferences

BOSTON, January 04, 2022--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate virtually at the following upcoming investor conferences:

Yahoo | January 4, 2022

Verastem, Inc. (NASDAQ:VSTM) COO Dan Paterson Sells 10,994 Shares

Verastem, Inc. (NASDAQ:VSTM) COO Dan Paterson sold 10,994 shares of the stock in a transaction on Monday, December 20th. The stock was sold at an average price of $2.27, for a total value of $24,956.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. []

Transcript Daily | December 23, 2021

-$0.08 EPS Expected for Verastem, Inc. (NASDAQ:VSTM) This Quarter

Brokerages expect Verastem, Inc. (NASDAQ:VSTM) to post ($0.08) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Verastems earnings. Verastem posted earnings per share of ($0.12) during the same quarter last year, which indicates a positive year over year growth rate of 33.3%. The company []

Dakota Financial News | December 6, 2021

Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Kamada (KMDA) and Verastem (VSTM)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (UHS – Research Report), Kamada (KMDA – Research Report) and Verastem (VSTM – Research Report) with bullish sentiments. Universal Health (UHS) In a report released yesterday, Ann Hynes from Mizuho Securities reiterated a Buy rating on Universal Health, with a price target of $151.00. The company's shares closed last Monday at $127.23, close to its 52-week low of $121.23. According to TipRanks.

Howard Kim on TipRanks | November 23, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4758 seconds.